Literature DB >> 8431967

Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.

L S Borman1, W G Bornmann, M E Kuehne.   

Abstract

Seven binary vinca alkaloid congeners were newly synthesized as the C14' or C16'(20') or C14'16'(20') stereoisomers of C20'-modified VBL. These congeners lacked detectable antimicrotubule activity in assays of polymerization of purified microtubule protein and of mitotic arrest induction. The compounds modulated the cytotoxicity of VBL, VCR, and DOX in sarcoma and colon-tumor cell lines. In wild-type cell lines, each congener elicited a concentration-dependent enhancement of cytotoxicity that was drug- and cell-type-selective. For example, C20'-deoxy C14'16'20'-epi VBL sensitized sarcoma S180 cells 19-fold to DOX and 11-fold to VCR but had no effect on VBL cytotoxicity. In the rat colon-cancer cell lines there was preferential enhancement of VCR cytotoxicity by most congeners. In two MDR cell strains of S180, the modulation potency of each congener was independent of specific drug or of resistance level. As a result, the amount of modulator (concentration) required for reversal was proportional to the drug-resistance level. Such properties were not displayed by the monomeric vinca alkaloid modulator vindoline. The potency of drug modulation in both wild-type and MDR cells strains was dependent on the stereoisomeric form of the congener and its C20'-substituents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431967     DOI: 10.1007/bf00686146

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  30 in total

1.  Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts.

Authors:  N Shudo; T Mizoguchi; T Kiyosue; M Arita; A Yoshimura; K Seto; R Sakoda; S Akiyama
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

Review 2.  Molecular biology of multidrug resistance in human cells.

Authors:  I H Pastan; M M Gottesman
Journal:  Important Adv Oncol       Date:  1988

3.  Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.

Authors:  H Arkin; T Ohnuma; B A Kamen; J F Holland; S Vallabhajosula
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

4.  Microtubule assembly in the absence of added nucleotides.

Authors:  M L Shelanski; F Gaskin; C R Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

5.  Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine.

Authors:  M Inaba; R Fujikura; S Tsukagoshi; Y Sakurai
Journal:  Biochem Pharmacol       Date:  1981-08-01       Impact factor: 5.858

6.  Reversal of multidrug resistance by non-antitumor anthracycline analogs.

Authors:  M Inaba; K Nagashima; Y Sakurai; M Fukui; Y Yanagi
Journal:  Gan       Date:  1984-12

7.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors:  R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

8.  Comparison of anthracycline concentrations in S180 cell lines of varying sensitivity.

Authors:  J M Siegfried; T R Tritton; A C Sartorelli
Journal:  Eur J Cancer Clin Oncol       Date:  1983-08

9.  Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog.

Authors:  S Akiyama; M M Cornwell; M Kuwano; I Pastan; M M Gottesman
Journal:  Mol Pharmacol       Date:  1988-02       Impact factor: 4.436

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  1 in total

Review 1.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.